The global collagen protein market is anticipated to grow at a considerable CAGR of around 5.4% during the forecast period. At present time, plant based natural products are in demand in every sector. People are looking for plant based alternatives for a clean and sustainable option. Many recent developments have taken place in the field of collagen which is animal free. People think it can benefit them in a much more efficient way. For instance, in Dec 2021, Geltor has announced its collaboration with K-beauty influencer Sally Olivia Kim. The company is looking forward to working on plant based collagen as Sally has also been working on this line of products. Collagen is taken as the main ingredient for cosmetic products due to its high moisturizing and regenerating properties.

The global lixisenatide market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. 

The global burkholderia pseudomallei infections drug market is anticipated to grow at a considerable CAGR during the forecast period. Infection caused by burkholderia pseudomallei bacterium is a rare disease and few options are available for their treatment. Government agencies and Pharma companies are keen on developing new therapy in form of biologics or biosimilars for such infections. For this, they are studying more about the characteristics and structure of the bacteria and how it reacts in different climates and regions. For instance, in Sept 2021, a Naval medical research center in the US has sent its team of research scientists to Australia to understand possible threats that can be caused by b pseudomallei bacteria in those regions. 

The global levofloxacin market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). A major element driving market expansion is hospital-acquired infection (HAI). Pneumonia, bloodstream infection, surgical site infection, and urinary tract infection are among the most frequent hospital-acquired infections. Government regulations to prevent and control hospital infections, the need for disinfectants and disposable safety goods to reduce the danger of infectious microorganisms will increase. 

The global integrin beta market is anticipated to grow at a considerable CAGR of around 6.5%during the forecast years. The increase in cancer cases all over the globe is driving the integrin beta market due to its increase the demand for integrin beta is also been increasing. For instance, As per the data released by International Agency for Research on Cancer (IARC), in 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths across the globe. The global burden is expected to grow to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040. 

The global Behcet disease drug market is anticipated to grow at a considerable CAGR during the forecast period. The use of biosimilars has increased in recent times. It will also rise in the future as biosimilars serve as a low-cost, easy option. Biosimilars are medicines that are close to biological drugs. They have the same characteristics, structure, and composition as biological drugs. Biologic drugs are those drugs that are made from several pieces of protein. Any brand drug has a parallel biosimilar to it. These biosimilars are safe and secure to consume when their efficacy is concerned. A drug that is of a particular brand also has its generic version.

The global influenza medication market is anticipated to grow at a considerable CAGR of 7.2% during the forecast period (2022-2028). All the major players in the influenza medication market are involved in strategic alliances like acquisitions, partnerships, collaborations, and the launching of new drugs and vaccines to provide advanced treatment for influenza disease globally. Recently, in January 2022, the ResVax vaccine, a vaccine developed by Novavax Co. for RSV disease has completed its phase four trial and the outcomes have been announced at the IDSOG meeting. 

The global antidepressant drugs market is anticipated to grow at a significant CAGR of 3.1% during the forecast period. Product innovations coupled with many leading advancements in antidepressant drugs are anticipated to drive the market in the coming years. For instance, in February 2022, Sage Therapeutics and Biogen announced that the phase 3 CORAL study met its primary and key secondary endpoints comparing Zuranolone 50 mg co-initiated with the standard of care antidepressant vs. standard of care co-initiated with Placebo in People with MDD. This will significantly help in the reduction of depression symptoms in people.  

Global vaso occlusive crisis associated with sickle cell disease market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028).  The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in September 2019, the US Government and Gates Foundation have pledged $200 million to bring gene therapy to patients with sickle diseases. 

The global end-stage kidney disease treatment market is anticipated to grow at considerable CAGR during the forecast period (2022-2028). Key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in January 2019, Fresenius Medical Care has launched a 4008A dialysis machine. The purpose of the launch was to improve the accessibility of high-standard dialysis treatment to patients who are suffering from end-stage kidney diseases with high-standard therapies while reducing the cost of health care systems